TCT 689: Mechanisms Leading to Peri-Procedural Myocardial Infarction in Patients With Focal Versus Diffuse Coronary Artery Disease

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker’s Bureau - Boston Scientific Corporation; Amgen